Amgen Stock Calculator
Estimate your Amgen ($AMGN) stock returns over time
Amgen Investment Calculator
Calculate potential returns on your Amgen stock investment using historical performance data.
Investment Projection Results
Initial Investment:
—
Hold Period:
—
Expected Annual Return:
—
Future Value:
—
Total Return:
—
What This Means For You
Enter your investment details above to see personalized insights.
Investment Growth Over Time
Frequently Asked Questions
This calculator allows you to project returns on Amgen stock over time. Input your initial investment, holding period, and return rate. Experiment with different values to see how compounding impacts your potential growth.
Amgen has demonstrated varying returns across different time periods. The 5Y return of 53.18% provides the most comprehensive historical view. Our weighted average annual return of 37.25% gives more weight to longer-term performance. However, past performance doesn't guarantee future results, and returns can vary significantly year to year.
Several factors can influence Amgen's stock performance:
- Company earnings and revenue growth
- Market conditions and economic trends
- Industry-specific developments
- Company announcements and news
- Overall market sentiment
The calculator provides two key metrics:
Future Value
The projected value of your investment at the end of your holding period
Total Return
The absolute dollar amount gained or lost, plus the percentage return on your investment
Remember that these are projections based on your inputs and historical data. Actual returns may differ significantly.
Explore More Stock Calculators
Historical Returns
1Y Return
-2.27%
2Y Return
39.70%
3Y Return
24.78%
4Y Return
38.29%
5Y Return
53.18%
YTD Return
13.58%
Last Updated: 2025-06-04 14:21:19
Amgen Information
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.
Business Classification
Sector
Healthcare
Industry
Drug Manufacturers - General
Location
Thousand Oaks, CA, United States
Company Size
28,000 employees
Website
Resources & Data Sources
Stock data powered by
Yahoo Finance API
Company logos provided by
Parqet Logo API
Market data and calculations are for informational purposes only and should not be considered as financial advice.
